Seng Chin Mah

Chairman at BioVersys AG

Health Technology

Commercial Services

Profile

Seng Chin Mah is currently the Chairman at BioVersys AG.
Prior to this, he held the position of Chief Executive Officer at Canyon Pharmaceuticals, Inc.

Seng Chin Mah active positions

Companies	Position	Start
BioVersys AG BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.	Chairman	-

All active positions of Seng Chin Mah

Former positions of Seng Chin Mah

Companies	Position	End
Canyon Pharmaceuticals, Inc. Canyon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Canyon Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. Its products include Revasc and Iprivask. The firm produces products to treat various immunity diseases. The company is headquartered in Hunt Valley, MD.	Chief Executive Officer	-

See the detail of Seng Chin Mah's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Seng Chin Mah's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Canyon Pharmaceuticals, Inc. Canyon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Canyon Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. Its products include Revasc and Iprivask. The firm produces products to treat various immunity diseases. The company is headquartered in Hunt Valley, MD.	Health Technology
BioVersys AG BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.	Commercial Services